CAJ | 학술논문

目的：观察晚期非小细胞肺癌表皮生长因子受体（ EGFR）敏感突变型患者酪氨酸激酶抑制药（ EGFR-tyrosine-kinase inhibitor，EGFR-TKI）的疗效和安全性。方法32例EGFR敏感突变型晚期非小细胞肺癌患者一线化疗后给予EGFR-TKI维持治疗。观察近期疗效、无进展生存期（progression-free-survival， PFS）、总生存期（overall survival， OS）及不良反应。结果全组CR 3例，PR 7例，SD 18例，PD 4例。有效率RR 31．3％，疾病控制率DCR 87．5％；中位PFS 14．9个月（95％CI：11．93～17．87个月）；中位OS 25．1个月（95％CI：20．8～29．3个月）。全组无重度不良反应发生，治疗耐受良好。皮疹发生率37．5％，腹泻发生率15．6％。结论晚期非小细胞肺癌EGFR敏感突变型患者EGFR-TKI维持治疗安全有效。
목적：관찰만기비소세포폐암표피생장인자수체（ EGFR）민감돌변형환자락안산격매억제약（ EGFR-tyrosine-kinase inhibitor，EGFR-TKI）적료효화안전성。방법32례EGFR민감돌변형만기비소세포폐암환자일선화료후급여EGFR-TKI유지치료。관찰근기료효、무진전생존기（progression-free-survival， PFS）、총생존기（overall survival， OS）급불량반응。결과전조CR 3례，PR 7례，SD 18례，PD 4례。유효솔RR 31．3％，질병공제솔DCR 87．5％；중위PFS 14．9개월（95％CI：11．93～17．87개월）；중위OS 25．1개월（95％CI：20．8～29．3개월）。전조무중도불량반응발생，치료내수량호。피진발생솔37．5％，복사발생솔15．6％。결론만기비소세포폐암EGFR민감돌변형환자EGFR-TKI유지치료안전유효。
Objective To investigate the efficacy and safety of EGFR-tyrosine-kinase inhibitor ( EGFR-TKI ) as maintenance therapy in patients with advanced non-small-cell lung cancer ( NSCLC) and positive EGFR mutation.Methods Thirty-two patients who suffered from advanced NSCLC with EGFR mutation-positive were given EGFR-TKIS ( Gefitinib, Taceva or Icotinib ) as mainte-nance therapy following first-line chemotherapy and no disease progression .Clinical efficacy , progression-free survival ( PFS) , overall survival (OS) and adverse events were analyzed.Results Complete remission(CR), partial remission(PR), stable disease(SD) and progressing disease(PD)were observed in 3, 7, 18 and 4 cases, respectively.Response rate (RR) was 31.3%and disease con-trol rate (DCR) was 87.5%in the group.Median PFS was 14.9 months(95%CI:11.93~17.87) and mOS was 25.1 months (95%CI:20.8~29.3).The most common adverse events were rash (37.5%) and diarrhea (15.6%).Conclusions EGFR-TKIs as ma-intenance therapy in the patients with advanced NSCLC and EGFR mutation-positive is effective and safe .